IDEXX Laboratories Inc

Chart & Performance

D1W1MN

P/E

46.50

P/S

10.59

EPS

11.04

Div Yield, %

—

Shrs. gr., 5y

-1.00%

Rev. gr., 5y

10.12%

Revenues

3.90b

+6.46%

Net income

888m

+5.07%

CFO

929m

+2.48%

Earnings

Aug 04, 2025

Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

URL

https://www.idexx.com/

IPO date

Jun 21, 1991

Employees

11,000

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	3,897,504 6.46%	3,660,953 8.72%	3,367,324 4.73%
Cost of revenue	2,769,167	2,563,825	2,468,559
Unusual Expense (Income)
NOPBT	1,128,337	1,097,128	898,765
NOPBT Margin	28.95%	29.97%	26.69%
Operating Taxes	221,964	216,134	180,883
Tax Rate	19.67%	19.70%	20.13%
NOPAT	906,373	880,994	717,882
Net income	887,867 5.07%	845,042 24.44%	679,089 -8.83%
Dividends
Dividend yield
Proceeds from repurchase of equity	(837,034)	(71,920)	(794,570)
BB yield	2.43%	0.15%	2.30%
Debt
Debt current	439,326	344,799	653,982
Long-term debt	645,458	842,027	816,051
Deferred revenue	26,939	28,533	30,862
Other long-term liabilities	44,341	65,526	168,826
Net debt	738,800	676,701	1,301,987
Cash flow
Cash from operating activities	929,001	906,510	542,984
CAPEX	(120,922)	(133,631)	(148,838)
Cash from investing activities	(207,062)	(125,254)	(195,350)
Cash from financing activities	(878,073)	(441,996)	(370,936)
FCF	870,631	598,775	445,083
Balance
Cash	288,266	453,932	112,546
Long term investments	57,718	56,193	55,500
Excess cash	151,109	327,077
Stockholders' equity	5,249,577	4,384,116	3,532,452
Invested Capital	2,502,432	2,318,865	2,108,247
ROIC	37.60%	39.80%	37.02%
ROCE	42.34%	41.35%	42.47%
EV
Common stock shares outstanding	83,246	83,978	84,600
Price	413.44 -25.51%	555.05 36.06%	407.96 -38.04%
Market cap	34,417,226 -26.16%	46,611,989 35.05%	34,513,416 -39.45%
EV	35,156,026	47,288,690	35,815,403
EBITDA	1,258,273	1,212,036	1,010,665
EV/EBITDA	27.94	39.02	35.44
Interest	31,205	41,581	38,793
Interest/NOPBT	2.77%	3.79%	4.32%